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Allergy-Associated FcRb Is a Molecular Amplifier
of IgE- and IgG-Mediated In Vivo Responses
reactions can be initiated through both of these recep-
tors. Clustering of FceRI-bound IgE by multivalent aller-
gens results in cellular degranulation and the release
David Dombrowicz,*§ Siqi Lin,* VeÂ ronique Flamand,*
Anna T. Brini,* Beverly H. Koller,²
and Jean-Pierre Kinet*³
of mediators of allergic reactions, including histamine,*Laboratory of Allergy and Immunology
leukotrienes, and various cytokines (Costa et al., 1997).Beth Israel Deaconess Medical Center, and
Similarly, clustering of FcgRIII with IgG-containing im-Department of Pathology
mune complexes activates mast cells and basophils toHarvard Medical School
produce anaphylactic reactions very similar to thoseBoston, Massachusetts 02215
induced through FceRI (Hazenbos et al., 1996; Dom-²Pulmonary Medicine
browicz et al., 1997; Miyajima et al., 1997). However, theUniversity of North Carolina at Chapel Hill
level of impact of FcRb on the function of these recep-Chapel Hill, North Carolina 27514
tors is unknown. Thus far, FcRb has only been consis-
tently detected in cells of mast cell or basophil lineage,
while in humans both FceRI and FcgRIII are also found
Summary without FcRb on many other cell types. Therefore,
whether the contribution of the subset of receptors that
A role for the Fc receptor b chain (FcRb) in the patho- contain FcRb could significantly impact an individual's
genesis of allergy has beensuggested by geneticstud- overall allergic response is an open question.
ies. FcRb is a subunit common to the high-affinity IgE Current studiesprovide directlyopposing conclusions
(FceRI) and low-affinity IgG (FcgRIII) receptors, both of as to how alterations of FcRb function might translate
which contribute to the initiation of allergic reactions. into altered FcR-mediated responses. In vitro data com-
Current in vitro data suggest that FcRb can function paring the signaling capacity of FceRIabg2 and ag2 re-
as either a positive or negative regulator, leaving a mech- ceptor complexes show that abg2 complexes induce
anistic explanation for its association with the devel- lyn-dependent tyrosine phosphorylation of FcRg chains,
opment of atopy unclear. To address this controversy, activation of the syk tyrosine kinase, and calcium mobili-
we have generated novel mouse models relevant to zation at a much higher level than their ag2 counterparts
human Fc receptor function. Analysis of FceRI- and (Scharenberg et al., 1995; Lin et al., 1996). In addition,
FcgRIII-dependent responses in these mice provides mutational analysis indicates that the immunoreceptor
unequivocal genetic evidence that FcRb functions as tyrosine-based activation motifs (ITAM) (Cambier, 1995)
an amplifier of early and late mast cell responses and, of the FcRb and FcRg chains have different functions
remarkably, in vivo anaphylactic responses. (Lin et al., 1996): the FcRg ITAM does the actual signal
transduction while the FcRb ITAM does not itself signal
but instead amplifies the FcRg signal. However, the tyro-Introduction
sine-phosphorylated ITAM of FcRb, but not that of FcRg,
binds to Src homology domain (SH2)±containing tyro-A role of the Fc receptor b chain (FcRb) gene in the
sine phosphatases (SHP-1 and SHP-2) and SH2-con-pathogenesis of human allergic diseases has been sug-
taining inositol-59-phosphatase (SHIP) in vitro, andgested by two types of genetic studies. First, a genetic
SHP-2 can be coprecipitated with FceRI after receptorlinkage was demonstrated between various atopic phe-
engagement (Kimura et al., 1997a, 1997b). As SHP-1,notypes and a region of human chromosome 11 encom-
SHP-2, and SHIP are phosphatases that participate inpassing the human (h) FcRb gene (Cookson et al., 1989;
negative signaling by receptors containing an immuno-Colee et al., 1993; Sandford et al., 1993; Shirakawa et
receptor tyrosine-based inhibitory motif (ITIM) (Schar-al., 1994a). Second, an association was found between
enberg and Kinet, 1996), these data would suggest thatthese atopic phenotypes and various polymorphisms
FcRb might have negative regulatory functions. The pos-located in the coding region of the FcRb gene (Shira-
itive signaling role of FcRb can be rationalized with itskawa et al., 1994b; Hill et al., 1995, 1996). However,
association with phosphatases by taking into accountwhether and how FcRb could significantly contribute to
the different cellular contexts in which the respectivethese allergic phenotypes remains unclear.
data were produced, and by the fact that the lyn tyrosineFcRb participates in the function of receptors involved
kinase (Jouvin et al., 1994; Kimura et al., 1996; Lin etin initiating allergic reactions. FcRb is a subunit of two
al., 1996) and SHIP/SHP-1 and SHP-2 phosphatasesrelated multisubunit receptor complexes, the high-affin-
(Kimura et al., 1997a, 1997b) appear to compete fority receptor for immunoglobulin E (IgE), FceRI, (Kinet et
binding to the FcRb ITAM. In this rationale, the respec-al., 1988; Blank et al., 1989, KuÈ ster et al., 1992) and
tive amounts of lyn kinase/phosphatases in a particularthe low-affinity receptor for immunoglobulin G, FcgRIII
context would play a major role in setting the level,(Kurosaki et al., 1992; Dombrowicz et al., 1997). Allergic
positive or negative, at which FcRb functions. This ratio-
nale, however, leaves open a critical question: what type
of signaling function does an in vivo context produce³To whom correspondence should be addressed (e-mail: jkinet@
for FcRb?mercury.bidmc.harvard.edu).
Unequivocally addressing the function of FcRb in vivo§Present Address: Institut Pasteur de Lille, INSERM, U167 Lille,
France. requires models in which FcRb is present or absent from
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Table 1. Structure and Cellular Distribution of FceRI
Mice Humans FceRIabg2 Mice FceRIag2 Mice
Mast cells abg2 abg2/ag2 abg2/ag2 ag2
Basophils abg2 abg2/ag2 abg2/ag2 ag2
Monocytes Ð ag2 ag2 ag2
Eosinophils Ð ag2 ag2 ag2
Langerhans cells Ð ag2 ag2 ag2
Dendritic cells Ð ag2 ? ?
its natural mast cell/basophil context and that otherwise Results
reflect hFcR function. Since allergic reactions can be
Reconstitution of the Structural Characteristicsinitiated by either FceRI or FcgRIII, it is further desirable
and Cell-Specific Expression of hFceRIto study FcRb function in both FceRI and FcgRIII con-
in Transgenic Micetexts. The construction of such models for FceRI is com-
To reconstitute FceRI with both its human cell-specificplicated by two differences between mouse and human
distribution and its alternative structures, we took ad-FceRI systems. First, the structure of FceRI varies ac-
vantage of two characteristics of the hFceRI system,cording to the species. In mice, FcRb is required for
one related to the promoter of the hFceRIa gene and thecell surface expression of FceRI so that FceRI is only
other to the subunit assembly. First, a 2.9 kb fragment 59expressed as abg2 tetramers on mast cells and baso-
of the initiation codon from the hFceRIa gene was activephils where both FcRb and FcRg are available (Ra et
in a reporter gene assay in mouse monocytic cells and,al., 1989), while in humans FcRb is dispensable for FceRI
as expected, in mast cells and basophils but not incell surface expression and FceRI can be expressed as
fibroblasts or T cells (data not shown), suggesting thatabg2 or ag2 complexes (Miller et al., 1989; KuÈ ster et al.,
the 2.9 kb sequence contained the information neces-1992). One consequence of the murine (m) requirement
sary to achieve the cell-specific expression of hFceRI.for FcRb is that gene targeting of FcRb in mice would
Based on these results, we anticipated that a transgenicresult in no FceRI expression, and would therefore not
mouse expressing the hFceRIa gene including the 2.9 kb
be a suitable approach for in vivo studies of how FceRI
promoter sequence would reconstitute the cell-specific
functions in the absence of FcRb. The second difference
pattern of expression observed in humans. Second, as
between the species is cell specificity of expression of discussed above, the subunit assembly characteristics
FceRI. In mice, FceRI is exclusively expressed on mast of human and murine FceRI are different. Thus, it was
cells and basophils. In contrast, in humans FceRI ex- further anticipated that a transgene of the complete
pression is less restricted and is expressed in the mast hFceRIa gene would result in assembly of hFceRIa with
cell and basophilic lineages as a mixture of abg2 or ag2 endogenous mouse FcRb and FcRg in mast cells and
complexes and as ag2 complexes on other hematopoi- basophils and in expression of a mixture of abg2 and ag2
etic cells, such as monocytes (Maurer et al., 1994), den- complexes on those cells and that in the other hFceRIa-
dritic cells (Maurer et al., 1996), Langerhans cells (Bieber expressing hematopoietic cells where FcRg but not
et al., 1992; Wang et al., 1992), and eosinophils (Gounni FcRb is expressed, such as monocytes, hFceRIa chain
et al., 1994) (Table 1). An important consequence of would assemble with FcRg and be expressed as ag2
these differences in expression specificity is that the complexes.
We generated transgenic mice using the completeproportion of FcRb-expressing FceRI in humans is much
hFceRIa gene under the control of the 2.9 kb promoter.smaller than in mice and, therefore, available mouse
The initial characterization of these mice was publishedmodels do not accurately reflect hIgE/FceRI physiology.
recently (Dombrowicz et al., 1996) and included the dem-In this manuscript, we describe the construction and
onstration that the hFceRIa protein is expressed in bonephenotypic characterization of mice with humanized ex-
marrow±derived cultured mast cells (BMMC), assemblespression of both FceRI abg2 and ag2 receptors or only
with endogenous mouse FcRb and FcRg, and promotesFceRIag2 receptors, along with a complementary set of
surface expression of abg2 complexes. In addition, thesemice that express both FcgRIIIabg2 and ag2 receptors
mice were shown to undergo hFceRI-mediated anaphy-or only FcgRIIIag2 receptors. Using these mice, we per-
lactic reactions, demonstrating the functionality of theformed both an in vitro analysis of the signaling role of
reconstituted receptors. As a further characterization of
FcRb in its natural cellular context and an in vivoanalysis
these mice (hFceRIa-transgenic, designated hFceRIaTg),
of the function of FcRb during FceRI- or FcgRIII-medi- we have analyzed the tissue specificity of expression
ated inflammatory responses.The results of theseanaly- of the hFceRIa transgene by measuring hFceRIa expres-
ses demonstrate that FcRb has the capacity to substan- sion on monocytes/macrophages, Langerhans cells,
tially affect the allergic responses of an individual and eosinophils. Figure 1A shows that hIgE binds to the
animal, and that it achieves this effect by functioning surface of BMMC and that this binding is inhibited by
as a net amplifier of in vivo responses in both FceRI and monoclonal anti-hFceRIa (15±1). Because stainings are
FcgRIII contexts. This strongly supports the concept performed with hIgE, which does not bind to mFceRI,
that the level of effector cell responsiveness determined only hFceRIa are detected. No hIgE binding was ob-
by FcRb can be an important determinant of human served on neutrophils obtained 2 hr after thioglycolate
elicitation (Figure 1B) or on thymocytes and splenocytesallergic responses.
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Figure 1. Tissue Distribution andStructure of
hFceRI in hFceRIaTg Mice
(A±E) Flow cytometric analysis of surface ex-
pression of hFceRI on BMMC (A), neutrophils
(B), eosinophils (C), thioglycolate-elicited mac-
rophages (D), and Langerhans cells (E) from
hFceRIaTg and FceRIa2/2 (control) (C, inset)
animals. Cells were stained with biotinylated
hIgE and SA-PE (A±D). Inhibition of hIgE bind-
ing by an excess of 15±1, thin line (A and C),
or inset (D). Dotted line (A±C), unstained cells.
(E) Double staining was performed with FITC-
15±1 and PE-labeled anti-CD45 or anti-MHC-
II (I-Ab,d). Values (percentages) are mean fluo-
rescence 6 standard error of the mean (SEM).
(F) Subunit structure of hFceRI at the surface
of thioglycolate-elicited macrophages,eosin-
ophils, and BMMC from hFceRIaTg animals.
Macrophages and eosinophils from FceRIa2/2
(hFceRIaTg-) mice were used as controls (lane
2). Macrophages and BMMC were incubated
with hIgE and then lysed with digitonin. hIgE-
receptor complexes were immunoprecipi-
tated with NIP±BSA sepharose beads. Eosin-
ophils and BMMC were incubated with 15±1,
washed, and then lysed, and antibody-recep-
tor complexes were immunoprecipitated with
Gammabind Plus sepharose beads. The im-
munoprecipitated material was blotted with
anti-FcRb and anti-FcRg antibodies after
SDS±polyacrylamide gel electrophoresis and
transferred onto polyvinylidene difluoride
membranes. Note that the bands migrating
below the 31 kDa marker on the anti-FcRb
immunoblot correspond to the light chain of
hIgE anti-NIP used in this experiment.
(data not shown). The hIgE binding capacity of eosino- Murine Langerhans cells express CD45 (leukocyte com-
mon antigen) and major histocompatibility complexphils from the peritoneal cavity of mice infected with
Schistosoma mansoni cercariae for 8±10 weeks (unin- class II (MHC-II) (I-A) but not T cell receptor (TCR) gd.
Langerhans cells and TCRad1 cells are the only twofected mice have very few eosinophils) is shown in Fig-
ure 1C. Binding of hIgE was also detected on bone CD451 cell populations found in normal epidermis (Elbe
et al., 1989). We performed multicolor flow cytometricmarrow and circulating eosinophils (data not shown).
This binding was inhibited by preincubation with an ex- analysis using phycoerythrin (PE)-labeled anti-CD45,
anti-I-A, anti-gd, or anti-c-Kit antibodies and fluoresceincess of 15±1 demonstrating the specificity of hFceRI±
hIgE interaction. The same population of peritoneal eo- isothiocyanate (FITC)±labeled 15±1. Double positive cells
CD45115±11 and MHC-II115±11 were identified in trans-sinophils obtained from nontransgenic animals was
devoid of hIgE binding (Figure 1C, inset) and of mIgE genic animals but not in control mice (Figure 1E). The
percentages of Langerhans cells (CD451MHC-II1) re-binding (data not shown). Thioglycollate-elicited perito-
neal macrophages also expressed hFceRI (Figure 1D). covered from the epidermis of both hFceRIaTg and con-
trol mice were similar (data not shown). In hFceRIaTgEpidermal Langerhans cells isolated from trunk skin of
hFceRIaTg mice also expressed hFceRI. Although mu- mice, 15±11 cells were gd2 and c-Kit2 (data not shown).
This binding pattern indicates that cells identifiable asrine Langerhans cells do not express a specific marker,
they can be identified by a group of cell surface markers. skin Langerhans cells from transgenic animals express
Immunity
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Figure 2. Gene Targeting of FcRb
(A) Organization of the FcRb gene. Map of
the WT gene, the targeting construct, and the
recombinant allele. Exons, closed boxes; in-
trons, open boxes; neo and tk cassettes,
striped boxes. Intron sizes were deduced
from the human gene sequence (KuÈster et al.,
1992) (GenBank accession number M89796).
Locations of the cloning sites (XhoI and XbaI)
and of the DraI restriction sites are indicated.
(B) Southern blot analysis of genomic DNA
from FcRb1/1, FcRb1/2, and FcRb2/2 mice.
DNA was digested with DraI. The probe used
is shown in (A).
(C) FceRI expression on BMMC from FcRb1/1,
FcRb1/2, and FcRb2/2 mice. BMMC were
stained with FITC-labeled mIgE and analyzed
by flow cytometry.
FceRI. Taken together, the above data indicate that hFceRIa on eosinophils from hFceRIaTg mice (Figure
1F, lane 3). In nontransgenic mice, neither FcRb northe hFceRIaTg mice have a cell expression pattern of
hFceRIa that is indistinguishable from that seen in FcRg was detected in macrophages and eosinophils
(Fig 1F, lane 2). Thus, these data demonstrate that thehumans.
We next assessed thesubunit structure of FceRI found hFceRIa transgene not only recapitulates the appro-
priate cell specificity of expression of hFceRI but alsoin various cell types from these mice. hIgE (anti-NIP
[4-hydroxy-3-nitrophenyl-acetyl]) was bound to thiogly- the appropriate cell type/structure pattern observed in
human cells (Table 1).colate-elicited peritoneal macrophages and BMMC from
hFceRIaTg and control animals. After washing, the cells
were lysed and the surface hFceRI receptors were im- Generation of FceRIabg2 and FceRIag2 Mice
To analyze the function of FcRb in a physiological con-munoprecipitated. The precipitates were then immuno-
blotted with monoclonal anti-FcRb (JRK) or polyclonal text, we chose to compare hFceRIaTg mice to corre-
sponding mice with the same hFceRIa cell distributionanti-FcRg antibodies, both of which react with the corre-
sponding murine subunits. mFcRb and mFcRg were im- but expressing only ag2 receptors. We reasoned that a
targeted disruptionof the mFcRb gene in these hFceRIaTgmunoprecipitated with hIgE in BMMC from hFceRIaTg
mice (Figure 1F, left, lane 1). By contrast, in macrophages mice should result in FceRI expressed only as ag2 com-
plexes. We first inactivated one mFcRb gene allele infrom hFceRIaTg mice, only FcRg was associated with
hFceRIa (Figure 1F, left, lane 3). The amount of FcRg embryonic stem (ES) cells and proceeded to generate
mice homozygous for this targeted mutation (Figuresassociated with hFceRIa was clearly less abundant in
macrophages than in BMMC despite the higher number 2A and 2B). Surface expression of mFceRI on BMMC
was similar in FcRb1/2 and wild-type (WT) mice (Figureof macrophages used in this experiment. Two factors
contributed to this result. The first is the lower number 2C, inset) but as expected from previous studies (Ra et
al., 1989) was abolished in FcRb2/2 mice (Figure 2C),of FceRI receptors expressed on macrophages when
compared to mast cells. The second is the lower deter- demonstrating the requirement of FcRb for surface ex-
pression of mFceRIa. FcRb2/2 mice were then crossedgent stability of the ag2 receptor complex resulting in
dissociation of the FcRg2 homodimer from the hFceRIa with hFceRIaTg mice. Progeny of the second generation
thus contained animals expressing the hFceRIa trans-chain, as previously described (Lin et al., 1996). Analysis
of eosinophil FceRI subunit structure was conducted in gene in the FcRb2/2 or FcRb1/2 background. For the
purpose of clarity, hFceRIaTg/FcRb1/2 and hFceRIaTg/a similar way. Eosinophils and control BMMC were first
saturated with 15±1, washed, and lysed, and the surface FcRb2/2 mice will be referred to as FceRIabg2 and
FceRIag2, respectively.receptors were immunoprecipitated. As in macrophages,
mFcRg but not mFcRb was found associated with A prerequisite for the analysis of the FcRb function
Allergy-Associated FcRb Is an In Vivo Amplifier
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Figure 3. Expression and Structure of FceRI
and FcgRIII on Peritoneal Cells and BMMC
(A±D) FceRI and FcgRIII expression on perito-
neal mast cells and macrophages from abg2
and ag2 mice. Flow cytometry analysis on
gated c-Kit1 (A and C) and MAC-11 (B and
D) cells after hIgE and 2.4G2 staining. Dotted
lines, unstained cells.
(E) Subunit structure of FceRI and FcgRIII ex-
pressed on the surface of BMMC. FceRI
structure was analyzed as described in Figure
1F (right), and FcgRIII structure was analyzed
similarly except that 2.4G2 was substituted
for 15±1 prior to immunoprecipitation with
protein A sepharose-bound anti-rat IgG.
by comparing the two types of mice is to insure that with FcRg alone. For the purpose of the desired compari-
son of FceRI function in the presence or absence ofhFceRI expression levels are equivalent on cells freshly
isolated from each strain. These levels were measured FcRb, it is therefore fortuitous that the presence of en-
dogenous mFceRIa as a competitor compensates forafter staining freshly isolated peritoneal mast cells and
macrophages from both types of mice with hIgE. Both the presence of FcRb as a facilitator of FceRI surface
expression.FceRIabg2 and FceRIag2 mice bind identical amounts of
hIgE, indicating that they express identical amounts of A second prerequisite for the analysis of the FcRb
function is to confirm that FceRIabg2 mice expressedsurface hFceRI on their peritoneal mast cells and macro-
phages (Figures 3A and 3B). Note that mast cells of tetrameric FceRI and that FceRIag2 mice expressed tri-
meric FceRI. Primary cultures of BMMC were generatedFceRIabg2 mice still express mFceRI while the FceRIag2
mice do not, because mFceRIa is not expressed on the and equal numbers of BMMC from each strain were
incubated with 15±1, washed, and lysed. The surfacecell surface in the absence of FcRb. In hFceRIaTg mice
in the FceRIa2/2 background (Dombrowicz et al., 1996), receptors bound to 15±1 were then immunoprecipitated
and analyzed by Western immunoblotting for the pres-mast cells do not express mFceRI, and these mice ex-
press higher levels of hFceRI on their mast cells when ence of FcRb and FcRg subunits (Figure 3E, left). As
predicted, the FceRIabg2 mice have detectable FcRbcompared to the corresponding FcRb2/2 mice (data not
shown). Thus, it seems that hFceRIa associates with and FcRg in anti-hFceRIa immunoprecipitates, while
FceRIag2 mice only have FcRg and no FcRb.endogenous FcRb and FcRg more efficiently than itdoes
Immunity
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These results demonstrate that the mast cells of 3C and 3D. The 2.4G2 antibody recognizes both FcgRII
and FcgRIII, so that this analysis can only give an ap-FceRIabg2 and FceRIag2 mice bind hIgE equivalently. In
addition, these mice express FceRI on the same cell proximate idea of the uniformity of FcgRIII expression.
However, studies of FcRg2/2 mice in which surface ex-types as in humans. They therefore represent an in vivo
model system with a human pattern of FceRI expression pression of FcgRIII is abolished suggest that between
50%±80% of 2.4G2 staining is due to FcgRIII (Takai etin which theeffect of FcRb on FceRI-mediated inflamma-
tory reactions can be studied. al., 1994). As can be seen, surface FcgR expression is
quite similar in the two strains, implying that FcgRIII
expression is also quite similar. Analysis of peritoneal
Generation of FcgRIIIabg2 and FcgRIIIag2 Mice mast cells and macrophages from WT mice in parallel
A second focus of this work was to examine whether with the above showed that 2.4G2 staining was weaker
FcRb might affect immune complex±mediated allergic than on either of the above (data not shown).
responses, since it is able to associate with FcgRIII as The subunit composition of the FcgR was character-
well as FceRI. Therefore, we chose to create murine ized on 2.4G2 immunoprecipitates of BMMC from both
models in which FcgR-mediated responses could be FcgRIIIabg2 and FcgRIIIag2 strains of mice (Figure 3E,
compared in the presence or absence of FcRb. As with right). As illustrated, 2.4G2 immunoprecipitates from
FceRI, the difference in complexity between mouse and FcgRIIIabg2 mice contain both FcRb and FcRg, while
human FcgR systems was important to consider prior those from FcgRIIIag2 mice contain only FcRg. The lower
to chosing a strategy for construction of these models. levels of FcRg seen in the lane for the FcgRIIIag2 strain
Two types of low-affinity receptors, FcgRII and FcgRIII, is probably due to the lower detergent stability of the
bind IgG-containing complexes in mice, and both are FcgRIIIag2 complexes, as expected based on what is
involved in the initiation of inflammatory responses me- seen for analogous FceRI complexes. Since 2.4G2 does
diated by these immune complexes. While FcgRII in not discriminate between mouse FcgRIII and FcgRII, the
mice mediate solely inhibitory signals through its ITIM, association between FcRb and FcgRIII was confirmed
in humans FcgRII can mediate either inhibitory (FcgRIIB) by immunoprecipitation with antibodies specific for the
or activating signals (FcgRIIA) depending on the pres- FcgRIII and FcgRII cytoplasmic tails followed by West-
ence of an ITIM or an ITAM in its cytoplasmic tail (Cam- ern immunoblotting for FcRb, which revealed an associ-
bier et al., 1995; Daeron et al., 1997). However, when ation only between FcRb and FcgRIII (Dombrowicz et
FcgRII and FcgRIII are viewed together as a low-affinity al., 1997). Taken together, the results demonstrate that
IgG receptor class, the overall distribution of inhibitory these mice are appropriate models in which to analyze
and activating subtypes is conserved such that distinct the role of FcRb in the regulation of in vivo allergic
effector cell types in the two species respond to immune reactions initiated through FcgRIII.
complexes in very similar ways. Unlike FceRI, both mouse
and human FcgRIIIa can be expressed as either ag2 or Role of FcRb in Early Signaling Mediated
abg2 receptors depending on whether FcRb is present. through FceRI
Therefore, a full FcgRIIIag2 phenotype is generated sim- As discussed above, data on FcRb function in the FceRI
ply via elimination of FcRb expression, and FcRb2/2 context suggest directly opposing functions for FcRb
mice can be used as a model of solely FcgRIIIag2-initi- as either a positive or negative regulator of signaling.
ated responses. However, these mice show an up-regu- As a first step to address this apparent discrepancy, we
lation of FcgRIII surface expression relative to WT mice, examined how the presence of FcRb affected signaling
presumably because mFceRIa, which requires FcRb for in its natural mast cell context by comparing FceRI sig-
surface expression, is then no longer available to com- naling in normal mast cells obtained from FceRIabg2 and
pete with FcgRIIIa for available FcRg chains (Dombro- FceRIag2 mice, focusing on the role of FcRb for the
wicz et al., 1997). To compensate for this, we chose to generation of early intracellular signals mediated through
use mFceRIa2/2 mice as our primary comparative model FceRI. BMMC were stimulated in such a way that the
of FcgRIIIabg2-mediated responses because mFceRIa number of receptors engaged with hIgE and antigen on
is then also no longer available to compete with mFcgRIIIa cells from FceRIag2 animals was equal or greater than
for FcRb, and these mice have an up-regulation of the ones on cells from corresponding FceRIabg2 mice
FcgRIII surface expression that is similar to that of the (Figure 4A). After stimulation with hIgE and its cognate
FcRb2/2 mice (see results below). Note that our analyses antigen, cells were lysed and tyrosine phosphorylation
below also included WT mice in parallel for comparison of the FcRg chain and Syk was analyzed by anti-FcRg
purposes although their lower level of FcgRIII expres- and anti-Syk immunoprecipitation, and the respective
sion precludes unambiguous interpretation of their re- immunoprecipitates were immunoblotted with an anti-
sponses.Asabove, for the purpose of clarity the FceRIa2/2 phosphotyrosine antibody. The tyrosine phosphoryla-
mice (which express mFcgRIIIabg2 receptors) and the tion state of Syk is known to closely parallel its activation
FcRb2/2 mice (which express FcgRIIIab2 receptors) will state. Engagement of FceRIabg2 induces much greater
be referred to as FcgRIIIabg2 and FcgRIIIag2 mice, re- FcRg and syk tyrosine phosphorylation than does en-
spectively. gagement of FceRIag2 (Figure 4B). We then compared
Documentation of receptor expression and composi- calcium mobilization in BMMC derived from these mice
tion are also prerequisites for experimental analysis of (Figure 5A). Calcium mobilization in the BMMC that ex-
the FcgRIII mice. Analysis of the surface expression of pressed FceRIabg2 was enhanced relative to that in the
FcgR on peritoneal mast cells and macrophages from BMMC expressing FceRIag2. Both of these results paral-
leled observations in the reconstitution and cultured cellthe FcgRIIIabg2 and FcgRIIIag2 mice is shown in Figures
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plus a secondary cross-linker (Figure 4B). In these ex-
periments, the number of receptors engaged with 2.4G2
on BMMC from FcgRIIIag2 mice was equal or greater
than the one on cells from FcgRIIIabg2 animals (Fig-
ure 4A). Since both inhibitory (FcgRII) and stimulatory
(FcgRIII) FcgR are expressed on mast cells (Alber et al.,
1992; Daeron et al., 1997), and 2.4G2 binds to both
FcgRII and FcgRIII, this antibody provides a stimulus
that is somewhat analogous to that induced by immune
complexes that engage both receptors. Tyrosine phos-
phorylation of FcRg and Syk was detected in FcgRIIIabg2
BMMC when stimulated with 2.4G2 alone, while neither
tyrosine-phosphorylated FcRg nor syk was detectable
after stimulation of FcgRIIIag2 BMMC (Figure 4B). If a
secondary cross-linker was added, the FcRg/syk tyro-
sine phosphorylation signals were further enhanced in
the FcgRIIIabg2 BMMC and became detectable in the
FcgRIIIag2 BMMC. Consistent with these results, no cal-
cium mobilization was observed in FcgRIIIag2 BMMC
stimulated with low (data not shown) or high doses (1
mg/106 cells) of 2.4G2 antibodies. In contrast, FcgRIIIabg2
cells exhibited a strong calcium response even with a
low-dose stimulus (10 ng/106 cells). However, subse-
quent addition of anti-rat IgG was able to induce calcium
mobilization in FcgRIIIag2 BMMC, although the flux was
still weaker than in FcgRIIIabg2 cells despite prior deple-
tion of calcium stores by 2.4G2 alone (Figure 5B). The
Figure 4. FcRb Amplifies Phosphorylation of FceRI and FcgRIII on
latter results demonstrate that stimuli producing smallBMMC
FcgRIII clusters (dimers with 2.4G2) are sufficient to trig-
(A) Flow cytometric analysis of FceRI and FcgRIII ligand occupancy
ger FcgRIIIabg2 but not FcgRIIIag2 BMMC. Conversely,at the time of BMMC stimulation. BMMC from FceRI abg2 and ag2
in the absence of FcRb larger clusters (obtained aftermice were incubated with 50 ng/ml per 106 cells hIgE; BMMC from
FcgRIIIabg2 and ag2 mice were incubated with 100 ng/ml per 106 secondary cross-linking) were required to induce signal-
cells and 1 mg/ml per 106 cells of the 2.4G2 antibody, respectively, ing. Therefore, these data indicate that FcRb is able to
to insure that the number of receptors engaged on cells from ag2 amplify signaling through FcgRIII.
mice was equal or higher than the ones from abg2 animals.
(B) FcRb amplifies FcRg and Syk tyrosine phosphorylation in BMMC
through FceRI and FcgRIII. BMMC were incubated with hIgE and
FcRb Function in Late Effector Responsestriggered or not with antigen; BMMC were triggered with 2.4G2
We next investigated whether the differences observedalone or not and further stimulated or not by cross-linking with anti-
rat IgG. Lysates were immunoprecipitated with anti-FcRg or anti- in these early intracellular signaling events (occurring
Syk antibodies, and the products were analyzed by immunoblotting within 1±5 min after the initial stimulus) could be trans-
with anti-phosphotyrosine antibodies. lated into meaningful differences in mast cell degranula-
tion and cytokine release, two responses that are ob-
served after long periods of stimulation (several minutes
models. Estimation of the extent of enhancement seen to 6 hr) and are directly relevant to the pathogenesis of
for each of these early parameters suggests that the FcRb allergic diseases. Degranulation of BMMC expressing
gain in these systems is around 5- to 10-fold, nearly FceRIag2 or abg2 was induced by cross-linking receptor-
identical to our previous results from transfected cul- bound IgE with multivalent antigen. An antigen dose-
tured cell models. These results substantiate the FcRb response experiment (Figure 5C) demonstrates that
amplifier concept for early signaling events mediated FcRb's presence amplifies the cell degranulation re-
by FceRI in a natural mast cell context. sponse through FceRI with a gain factor of 3- to 5-fold.
Similar results were obtained when BMMC were trig-
gered using 15±1 with further cross-linking (Figure 5D).Role of FcRb in Early Signaling Mediated
through FcgRIII However, cross-linking with 15±1 alone did not induce
a measurable response. We also analyzed the degranu-Although previous studies have not detected differences
in signaling between FcgRIIIabg2 versus ag2 , the sub- lation response of BMMC after stimulation with 2.4G2.
Initiation of degranulation responses of BMMC viastantial homology between FceRIa and FcgRIIIa and the
clear amplifying effect of FcRb on FceRIa signaling led FcgRIII followed the same general pattern as via FceRI.
Very little degranulation was seen after FcgRIIIag2 en-us to reexamine the effect of FcRb on FcgRIII early sig-
naling using BMMC from the FcgRIIIabg2 and FcgRIIIag2 gagement with 2.4G2 alone, while identically stimulated
FcgRIIIabg2 cells released 35% (maximum) of their totalmice. FcgRIII-dependent signaling was analyzed by
comparing FcRg tyrosine phosphorylation and Syk tyro- content (Figure 5E). Analysis of the effect of FcRb on
cytokine release was performed by measuring interleu-sine phosphorylation induced through FcgRIII cross-
linking with the rat monoclonal antibody 2.4G2 or 2.4G2 kin (IL)-6 production after cell triggering via FceRI or
Immunity
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Figure 5. FcRb Amplifies BMMC Calcium
Mobilization, Degranulation, and IL-6 Release
through FceRI and FcgRIII
(A) FceRI-induced calcium mobilization. BMMC
from FceRIabg2 and ag2 mice were loaded
with Fura-2 and 50 ng/ml per 106 cells anti-
NIP hIgE before being stimulated with NIP±
BSA (12 ng/ml per 106 cells).
(B) FcgRIII-induced calcium mobilization.
Fura-2±loaded BMMC from FcgRIIIabg2 and
ag2 mice were stimulated with 10 or 100 ng
or 1 mg/ml per 106 cells of 2.4G2 and further
cross-linked with 10 mg/ml of anti-rat IgG.
(C and D) FceRI-induced degranulation as
measured by b-hexoseaminidase release. (C)
BMMC from FceRIabg2 and ag2 mice were
incubated with 25 or 50 ng/ml per 106 cells
hIgE and stimulated with NIP±BSA antigen.
(D) BMMC from FceRIabg2 and ag2 mice were
triggered with increasing doses of anti-
hFceRIa (15.1) antibody and further cross-
linked or not with 10 mg/ml of anti-mouse IgG
F(ab9)2 fragments. Values are means 6 SEM;
when not visible, error bars are within the
symbols.
(E) FcgRIII-induced degranulation as mea-
sured by b-hexoseaminidase release. BMMC
from FcgRIIIabg2 and ag2 mice were stimu-
lated with increasing doses of 2.4G2 antibody
and further cross-linked or not with 10 mg/ml
anti-rat IgG. Values are means 6 SEM; when
not visible, error bars are within the symbols.
(F) IL-6 production; BMMC from FceRIabg2
and ag2 mice were loaded with 50 ng/ml per
106 cells anti-NIP hIgE and then stimulated
with NIP±BSA; BMMC from FcgRIIIabg2 and
ag2 mice were triggered with 1, 10, and 100
ng/ml per 106 cells of 2.4G2 antibody. Culture
medium samples were removed after 6 hr
stimulation. Values are means 6 SEM; when
not visible, error bars are within the symbols.
FcgRIII (Figure 5F). IL-6 production in abg2 BMMC was FceRI to produce significant anaphylactic responses.
Therefore, to verify that our IgE sensitization protocolhigher than in ag2 BMMC after stimulation with either
FceRI or FcgRIII. Thus, FcRb is not only able to amplify would produce loading of both mast cells and nonmast
cells, we first examined in situ hIgE binding on peritonealearly intracellular signaling events in mast cells but also
later effector responses. In addition, the amplification mast cells and macrophages 24 hr after the injection of
100 mg of anti-NIP hIgE. The data presented in Figureseffect of FcRb on these effector responses is of suffi-
cient magnitude that its presence produces large re- 3A and 3B show that the peritoneal mast cells and mac-
rophages of FceRIabg2 and FceRIag2 mice express simi-sponses to stimuli that would otherwise produce little
or no response (as in the case of degranulation and lar levels of hFceRI as assessed by exposure ex vivo to
a saturating amount of ligand. After in situ exposure tocytokine production induced by stimulation with 2.4G2
alone). hIgE, there is detectable bound hIgE that is equal in
both the FceRIabg2 and FceRIag2 mice, although the
level of receptor occupancy is much lower than satura-Role of FcRb in IgE-Mediated Allergic Responses
We have demonstrated that FcRb amplifies IgE- and tion (compare Figure 6A with the level of cell fluores-
cence produced when the receptors are saturated [Fig-IgG-mediated early and late mast cell responses in vitro.
The next step was to determine whether the amplifying ures 3A and 3B]). When using this injection protocol
followed by administration of antigen to promote sys-function observed in vitro would translate into measur-
able differences in in vivo responses. Since FcRb ex- temic anaphylaxis, only small anaphylactic responses
were elicited (as measured by rectal temperature drop)pression is restricted to mast cells and basophils and
the majority of the FceRI receptors in the humanized (data not shown), and we were unable to detect any
difference between the FceRIabg2 and FceRIag2 mice.mouse model are, as in humans, in the form of ag2 com-
plexes, it was not a priori obvious that the FcRb amplifi- Since the in situ data indicated that at best only one
tenth of hFceRI receptors were bound with hIgE usingcation effect would have a significant impact on in vivo
responses in these mice. In addition, the broadened this protocol, we inferred that the overall IgE binding
capacity of these mice is such that 100 mg of IgE is notexpression range of hFceRI produces a large number of
nonmast cell-expressing FceRIag2, raising the possibil- adequate to produce a high enough receptor saturation
level to produce a robust in vivo anaphylactic response.ity that it might be difficult to adequately load mast cell
Allergy-Associated FcRb Is an In Vivo Amplifier
525
Figure 6. FcRb Amplifies Systemic Anaphy-
laxis through FceRI and FcgRIII
(A) FceRI ligand occupancy on peritoneal
mast cells and macrophages 24 hr after intra-
venous injection of 100 mg hIgE. Flow cy-
tometric analysis of gated c-Kit1 (left) and
MAC-11 (right) cells showed that receptor en-
gagement was similar in FceRI abg2 and ag2
mice. Dotted line, unstained cells.
(B) Rectal temperature changes in FceRIabg2
and ag2 mice (n 5 4) after 3 intravenous injec-
tions at 12 hr intervals of 50 ng of anti-NIP
hIgE and intravenous challenge, 4 hr after the
last injection, with 1 mg of NIP±BSA. Controls
(FceRIabg2, n 5 3; FceRIag2, n 5 2) received
NIP±BSA only. Data show mean values 1 SEM;
p, 0.001 by ANOVA versus data from control
mice (1) or versus FceRIag2 mice (#).
(C) Rectal temperature changes in FcgRIII-
abg2 (n 5 9) and FcgRIII ag2 (n 5 7) mice after
intravenous injection of 100 mg 2.4G2. Control
animals (n 5 3) received an equal amount of
nonspecific rat IgG. Values are means 6 SD;
p, 0.005 by ANOVA versus control mice (1)
or versus FcgRIIIag2 (#).
(D) Rectal temperature changes in FcgRIIIabg2
(n 5 23) and FcgRIIIag2 (n 5 9) mice after iv
injection of 400 mg anti-DNP IgG1 and chal-
lenge with 1 mg DNP-HSA 24 hr later. Control
animals (n 5 15) received an equal amount of nonspecific mouse IgG and were challenged as described. Values are means 6 SD; p, 0.005
by ANOVA versus control mice (1) or versus FcgRIIIag2 (#).
(C and D) Note that the FcgRIIIabg2 and control temperature curves were from a large contemporaneously generated data set that included
control, WT, and FcRg2/2 together with FcgRIIIabg2 (Dombrowicz et al., 1997), and FcgRIIIag2 (unpublished data); the data on FcgRIIIabg2
mice and control that have been previously published (Dombrowicz et al., 1997) are therefore shown with a dotted line.
Based on the above data, we designed a new protocol to control values (Figure 6C). By comparison, the temper-
ature drop induced by 2.4G2 injection in the FcgRIIIag2of three consecutive injections of IgE with the intention
of producing a higher receptor saturation level prior to mice was reduced to only 28C relative to control values.
Preformed immune complexes composed of anti-DNPantigenic challenge. FceRIabg2 and FceRIag2 mice were
injected three times at 12 hr intervals with 50 mg of anti- (dinitrophenyl) IgG1 and the corresponding antigen (DNP-
HSA [human serum albumin]) duplicated almost per-NIP hIgE before being challenged intravenously with the
corresponding antigen (NIP±BSA [bovine serum albu- fectly the results obtained with the 2.4G2 stimulus in
FcgRIIIabg2 and ag2 mice (Figure 6D). Analysis of themin]). In these conditions, FceRIabg2 mice displayed a
strong temperature drop (5.78C) after30 min. In contrast, level of amplification indicates that FcRb provides a gain
factor of around 3. In addition, we performed a parallelFceRIag2 mice had a much weaker response (2.08C drop
after 10 min) and completely recovered after 40 min analysis of WT mice, which express a lower level of
surface FcgRIII (a subset of which contains FcRb) than(Figure 6B), a response reminiscent of the one described
above for both types of mice after a single 100 mg loading do the FcgRIIIag2 mice. While respondingly less ro-
bustly than the FcgRIIIabg2 mice, the WT mice showedwith IgE. Taken together these data demonstrate that
FcRb displays an amplifier effect on IgE-mediated re- a temperature drop (approximately 4 degrees) (data not
shown) that was statistically significantly larger than thesponses in vivo with a gain of about 5-fold and suggest
that the manifestation of this amplifier effect in an in FcgRIIIag2 mice in spite of the lower level of FcgRIII
expressed in the WT mice, implying that the FcRb ampli-vivo response depends at least in part on an adequate
level of saturation of mast cell FceRIabg2 receptors. fication effect is responsible for a substantial proportion
of the anaphylactic responses under normal conditions.
Therefore, the ability of FcRb to amplify mast cell ef-Role of FcRb in IgG-Mediated Allergic
Responses In Vivo fector responses in vitro translates into a marked
enhancement in anaphylactic responses mediated viaTo determine whether FcRb could also play a role in
FcgRIII-mediated systemic anaphylactic responses, the either FceRI or FcgRIII.
FcgRIIIabg2 and FcgRIIIag2 mice were injected either
with 2.4G2 antibodies or with IgG-containing immune Discussion
complexes and monitored for anaphylactic responses
by body temperature measurements. We verified that In this paper, we have generated mice with distinct FceRI
and FcgRIII structural phenotypes and used them tothe in situ loading of mast cells and macrophages was
equivalent or lower in FcgRIIIabg2 animals compared to compare cellular and whole animal responses mediated
by the two receptors functioning with or without FcRb.FcgRIIIag2 mice (data not shown). A single intravenous
injection with 100 mg of 2.4G2 results in a maximal drop The data presented are unequivocal genetic evidence
that FcRb has the capacity to substantially modulatein body temperature of 88C in FcgRIIIabg2 mice relative
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an individual animal's allergic response, and that this to speculate that enhanced IgE- or IgG/FceRI immune
complex-mediated activation of mast cells and baso-capacity is due to its function as a net amplifier of ef-
fector cell responses. phils in response to invading pathogens (Zhang et al.,
1992; Echtenacher et al., 1996; Malaviya et al., 1996) viaAs discussed in the introduction, FcRb has been sug-
gested to play a role in the development of atopy. How- increased expression or qualitatively more active FcRb
has provided a selective advantage that has driven theever, the idea that effector cell responses could vary
significantly enough among different individuals to have accumulation of atopy-associated forms of FcRb in
modern human populations.an important impact on the development of allergic re-
sponses has been very controversial. In fact, while atopy In summary, we have created and characterized two
novel murine models that are relevant to hFcR function.is widely regarded as a multifactorial disease, most
models of atopy focus on the dysregulation of cellular Using these mice as a model system, we have shown
that FcRb functions in its natural context as a net ampli-(e.g., T helper type 1 or T helper type 2) and humoral
responses that are responsible for the initial production fier of FceRI- and FcgRIII-mediated mast cell activation
and in vivo responses and have formally demonstratedof high levels of allergen-specific IgE. However, our data
directly demonstrate the importanceof FcRb in the man- the importance of the level of effector cell responsive-
ness in the manifestation of an allergic response. Thisifestation of allergic responses: animals that lack FcRb
have such substantially reduced responses that no de- information provides an important conceptual basis for
understanding how polymorphic forms of FcRb mightgree of dysregulation of humoral responses would be
able to produce a sufficient level of sensitization to allow contribute to or retard the development of human atopy.
them to manifest as atopic. The large effect that FcRb
Experimental Procedureshas on allergic responses in both FceRI and FcgRIII
receptor contexts is a formal demonstration of the ca-
Targeting of the FcRb Genepacity of FcRb to contribute to allergic responses. In
The mouse FcRb gene was isolated from a 129l DASH library (a
addition, we present biochemical data, in vitro cell acti- gift from P. Love, National Institutes of Health [NIH], Bethesda, MD).
vation data, and in vivo inflammatory response data that Targeted disruption of the gene was achieved by replacement of
exons IV±VI (corresponding to base pairs [bp] 344±577 of the mFcRbshow that FcRb functions as a net amplifier of FceRI and
cDNA sequence) (Ra et al., 1989) with a neo cassette. A 4 kb frag-FcgRIII effector cell responses. Together, these dem-
ment encompassing exons I±IV (bp 38±343 of the mouse FcRb cDNAonstrations strongly support the concept that atopy-
sequence) and a 1.4 kb fragment encompassing exons VI±VII (bpassociated isoforms of FcRb may contribute to the mani-
578±1007) were amplified by polymerase chain reaction using ap-
festation of atopy through some modulation of FcRb's propriate primers and cloned respectively into the XhoI and XbaI of
ability to promote effector responses in vivoand provide the pJNS2 vector (Dombrowicz et al., 1993). The construct was
linearized by NotI and electroporated into D3 or E14 TG2a ES cells.a strong rationale for proceeding with the investigation
ES cells were grown and selected as previously described (Kollerof the functional effect of FcRb polymorphisms on the
and Smithies, 1989). Genomic DNA was extracted from clonal ESgain provided by FcRb.
cells, digested with DraI, and hybridized by Southern blot to a 440Given that FcRb is able to have an important influence
bp fragment located 16 bp downstream of exon VII. The hybridizing
on the manifestation of atopy via its role in setting the bands were 3.4 kb for the WT and 2.8 kb for the disrupted allele.
level of effector cell responses, what types of polymor- Two of 109 G418-resistant, ganciclovir-sensitive clones were found
positive for homologous recombination.phisms would one logically expect to find? Obvious pos-
sibilities that would result in a gain of function include
Animalspolymorphisms in the promoter or regulatory regions
Chimeric, heterozygous (1/2), and homozygous (2/2) animals forresulting in increasing FcRb expression, polymorphisms
the disrupted FcRb allele were generated as previously described
in the transmembrane domains capable of increasing (Koller and Smithies, 1989); FcRb2/2 animals were on a BALB/c
assembly and the proportion of abg2 complexes ex- F2 background. FceRIa2/2 animals have been previously described
(Dombrowicz et al., 1993) and were on a BALB/c F6 background.pressed on effector cells, and polymorphisms around
FcRb2/2 animals were compared to age-matched FceRIa2/2 for allthe ITAM that could stabilize association with kinases
relevant experiments.FcRb2/2 were also crossed with the previouslyor destabilize association with phosphatases. However,
described transgenic mice for the hFceRIa gene (hFceRIaTg) (Dom-polymorphisms that would be dominant in the nonaller-
browicz et al., 1996). Progeny of the second generation thus con-
gic population should also be considered. For example, tained hFceRIaTg/FcRb2/2 or hFceRIaTg/FcRb1/2 animals. Lit-
it is conceivable that alleles of inactive or less active termates were used in all appropriate experiments. hFceRIaTg mice
FcRb (for example ITAM-less or ITAM-mutant FcRb) used for these crosses were in a BALB/c WT background, so that
hFceRIaTg/FcRb1/2 animals were expressing both human and mu-have been overlooked in nonallergics. When a particular
rine FceRI on their mast cells. Animals used for the study of hFceRIpolymorphism has shown a potential functional effect
cellular distribution were on a FceRIa2/2 background and thus werein vitro, the animal model developed and used here
expressing only hFceRI.
should be adaptable for testing the function of polymor-
phisms in vivo. Cells
Our analyses of these mice also provide an intriguing Peritoneal Cells
Peritoneal cells were obtained by flushing the peritoneal cavity withinsight into hFcR biology. The large differences in magni-
2 3 10 ml of ice-cold Hanks' balanced salt solution containing 1%tude of response between the FcgRIIIag2 and FcgRIIIabg2
fetal calf serum and 10 IU/ml heparin. Cells were collected on icemice after exposure to the weak 2.4G2 stimulus demon-
and the clumps removed by filtration on nylon filters. Thioglycollate-
strates that the FcRb amplifier may be particularly im- elicited macrophages wereobtained 72 hr after intraperitoneal injec-
portant for immune responses to weak stimuli, such as tion with 1 ml of 5% thioglycolate. After overnight cultures, adherent
might be encountered in the earliest stages of inflamma- cells were used for flow cytometry analysis. For Western blotting
experiments, peritoneal cells were incubated at 106 cells/ml with 10tory responses to invading pathogens. It is tempting
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mg/ml collagen-coated dextran beads (Cytodex 3, Pharmacia) for of hIgE binding was performed as described above. A dose of 50
ng/ml per 106 cells resulted in a similar loading of cells from both8 hr and adherentmacrophages harvested by collagenasetreatment
(500 mg/ml). FceRIabg2 and ag2 animals. Likewise, to determine the dose of 2.4G2
necessary for engagement of the same number of receptors onNeutrophils
Neutrophils were collected 2 hr after thioglycolate injection as non- BMMC from FcgRIIIabg2 and ag2 mice, cells were incubated for 20
min at 378C with 2.4G2 doses ranging from 10 ng to 1 mg/ml peradherent cells.
Eosinophils 106 cells. Binding of 2.4G2 was revealed using FITC-labeled anti-
rat IgG. Similar and almost saturating loading was achieved withEosinophils were obtained from mice (6±12 weeks old) that had
been infected with 80 cercariae of S. mansoni and sacrificed 8 weeks 100 ng and 1 mg/ml per 106 cells of 2.4G2 for cells from FcgRIIIabg2
and ag2 mice, respectively.after infection (Williams et al., 1993). Peritoneal, bone marrow, and
blood eosinophils were harvested and cultured overnight in com- Experiments of phosphorylation and calcium mobilization were
performed as previously described, except that FceRI was triggeredplete RPMI containing 2.5 ng/ml murine IL-5 for removal of adhering
macrophages. Nonadherent cells were collected for analysis. Per- with 12 ng/ml NIP±BSA (Dombrowicz et al., 1996; Lin et al., 1996).
centage of eosinophils was determined after staining with Phloxine
B (Unopette, Becton Dickinson). Eosinophils represented 55% and Degranulation
45% of the peritoneal cells from transgenic and control animals, Cellular degranulation was measured by the release of b-hexose-
respectively. aminidase as described before, with minor modifications (Hirasawa
Langerhans Cells et al., 1995). Cells were incubated overnight with 50 ng/ml per 106
Epidermal cell suspensions were obtained as described (Schuler cells hIgE orwith various doses of anti-FceRIa (15±1) for 2 hr, washed
and Steinmann, 1985; Borkowski et al., 1996). twice, and stimulated with NIP±BSA or with 10 mg/ml goat anti-
BMMC mouse IgG F(ab9)2 for 20 min. Stimulation with 2.4G2 antibodies was
BMMC were obtained as previously described (Dombrowicz et al., performed for 25 min and, when appropriate, 10 mg/ml anti-rat IgG
1993, 1996). was added without prior washing, after 10 min incubation.
Flow Cytometry IL-6 Production
Flow cytometric analyses wereperformed on 3 3 105 cells as follows. IL-6 production was measured by enzyme-linked immunosorbent
All of the incubation steps were on ice for 30 min in 100 ml of assay (Endogen) on 50 ml of culture medium according to the manu-
phosphate-buffered saline (PBS) with 0.1% BSA and 0.05% sodium facturer's instructions, after 6 hr stimulation with 50 ng/ml per 106
azide.Unless specified otherwise, all of theantibody final concentra- cells hIgE and 1, 10, and 100 pg/ml per 106 cells of NIP±BSA or with
tions were 10 mg/ml. hFceRI expression was analyzed using three 1, 10, and 100 ng/ml per 106 cells 2.4G2.
different methods after saturation of FcgRII/III receptors with an
excess of unlabeled 2.4G2, a rat IgG2bk (Unkeless, 1979). A chimeric Anaphylaxis
hIgE molecule (Schwarzbaum et al., 1989), composed of an Fc por- Anaphylactic reactions were induced and measured as before (Dom-
tion of hIgE and of an anti-NIP F(ab) portion of mIgE and referred browicz et al., 1997) except that hIgE-induced systemic anaphylaxis
to as hIgE for the purpose of clarity, was used. After washing, hIgE was achieved by 3 iv injections of 50 mg of anti-NIP hIgE in 200 ml
was revealed with a biotinylated anti-mouse l11l2 light chains of PBS at 12 hr intervals followed 4 hr later by an iv challenge with
(Pharmingen) and streptavidin-phycoerythrin (SA-PE) (1:2500). Al- 1 mg of NIP±BSA in 200 ml of PBS.
ternatively, hFceRI was detected with biotinylated hIgE followed by
SA-PE or with FITC-labeled anti-FceRIa (15±1) (Wang et al., 1992).
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